RBC Capital analyst Leonid Timashev raised the price target on Insmed (NASDAQ: INSM) to $216.00 (from $212.00) while maintaining a Outperform rating.

The analyst comments "Investor focus continues to be centered around the Brinsupri launch - so we ran a survey of 50 physicians to better understand their initial experience using Brinsupri, and expectations for future prescribing. We found physicians liked Brinsupri's profile and expected to use more of the drug, and importantly, saw the potentially eligible population expanding dramatically. Meanwhile, risks look to be manageable, with payers not a major obstacle, and Brinsupri preferred over competitors. We remain convinced Brinsupri will deliver a 1Q26 beat, and are also taking up our longer term estimates to reflect bullish physician preferences, price target to $216 (from $212)."